Display options
Cite
Karakiewicz PI, Nott L, Joshi A, et al. Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma. Onco Targets Ther. 2016;9:2855-63doi: 10.2147/OTT.S102578.
Karakiewicz, P. I., Nott, L., Joshi, A., Kannourakis, G., Tarazi, J., & Alam, M. (2016). Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma. OncoTargets and therapy, 92855-63. https://doi.org/10.2147/OTT.S102578
Karakiewicz, Pierre I, et al. "Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma." OncoTargets and therapy vol. 9 (2016): 2855-63. doi: https://doi.org/10.2147/OTT.S102578
Karakiewicz PI, Nott L, Joshi A, Kannourakis G, Tarazi J, Alam M. Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma. Onco Targets Ther. 2016 May 12;9:2855-63. doi: 10.2147/OTT.S102578. eCollection 2016. PMID: 27274281; PMCID: PMC4869634.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2016 May 12;9:2855-63. doi: 10.2147/OTT.S102578. eCollection 2016.

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma.

OncoTargets and therapy

Pierre I Karakiewicz, Louise Nott, Abhishek Joshi, George Kannourakis, Jamal Tarazi, Mahmood Alam

Affiliations

  1. Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, QC, Canada.
  2. Department of Haematology and Oncology, Royal Hobart Hospital, Hobart, TAS, Australia.
  3. Townsville Cancer Centre, Townsville Hospital, James Cook University, Townsville, QLD, Australia.
  4. Fiona Elsey Cancer Research Institute, Ballarat, VIC, Australia; Ballarat Oncology and Haematology Services, Wendouree, VIC, Australia.
  5. Clinical Development, Pfizer Oncology, San Diego, CA, USA.
  6. Regional Medical Affairs, Pfizer Oncology, Asia Pacific Region, West Ryde, NSW, Australia.

PMID: 27274281 PMCID: PMC4869634 DOI: 10.2147/OTT.S102578

Abstract

BACKGROUND: Axitinib, a selective and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors, was available to patients from Canada and Australia, prior to regulatory approval of axitinib in these countries, for treatment of clear-cell metastatic renal cell carcinoma (mRCC) after failure of one prior systemic regimen.

METHODS: This single-arm, open-label study of axitinib evaluated the efficacy, safety, and quality of life (QoL) in patients with mRCC whose disease progressed after one prior systemic first-line regimen. Primary objective was objective response rate evaluated per Response Evaluation Criteria in Solid Tumors (RECIST) and Choi criteria. Progression-free survival, overall survival, safety, and QoL were secondary end points. Due to the small study size, analyses comprised of descriptive statistics.

RESULTS: Fifteen patients were recruited, five from Canada and ten from Australia, over a limited recruitment period. Thirteen patients received sunitinib as prior therapy. All patients had clear-cell carcinoma, eleven had prior nephrectomy. Liver, lung, and lymph nodes were the most frequent sites of metastases; one patient had brain metastasis. Median time on axitinib was 118.0 days (range: 3.5-645.0 days); estimated survival probability at 12 months was 57.8%. Two (13.3%) patients had objective responses per RECIST versus nine (60.0%) per Choi criteria. Six patients had progressive disease based on RECIST versus three per Choi criteria. Nine (60.0%) events of progression or death occurred by the end of study, and three patients continued to receive the study drug. Fatigue (33%) and diarrhea (20%) were the most common grade ≥3 all-causality, treatment-emergent adverse events. The mean change in European Quality of Life - 5 Dimensions score from baseline to end of treatment was -0.0837.

CONCLUSION: The small number of patients and lack of a comparator arm limit the ability to draw definitive conclusions; however, safety and efficacy profiles of axitinib were consistent with reports from previous studies in patients with mRCC, and patients generally maintained QoL. The sizeable difference observed in objective response rate by RECIST versus Choi criteria merits further research.

Keywords: RECIST; metastatic; objective response rate; vascular endothelial growth factor receptor inhibitor

References

  1. Cancer. 2012 Dec 1;118(23):5857-66 - PubMed
  2. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  3. Jpn J Clin Oncol. 2010 Oct;40(10 ):980-5 - PubMed
  4. N Engl J Med. 2007 Jan 11;356(2):115-24 - PubMed
  5. Jpn J Clin Oncol. 2007 Oct;37(10):755-62 - PubMed
  6. J Clin Oncol. 2004 Feb 1;22(3):454-63 - PubMed
  7. Ann Oncol. 2011 Aug;22(8):1828-33 - PubMed
  8. N Engl J Med. 2007 Jan 11;356(2):125-34 - PubMed
  9. Lancet Oncol. 2007 Nov;8(11):975-84 - PubMed
  10. Jpn J Clin Oncol. 2013 Jun;43(6):616-28 - PubMed
  11. BMC Cancer. 2013 Mar 21;13:136 - PubMed
  12. Jpn J Clin Oncol. 2010 Mar;40(3):194-202 - PubMed
  13. Jpn J Clin Oncol. 2011 Nov;41(11):1265-70 - PubMed
  14. Lancet. 2011 Dec 3;378(9807):1931-9 - PubMed
  15. Oncology. 2011;80(5-6):395-405 - PubMed
  16. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  17. Eur J Cancer. 2013 Apr;49(6):1287-96 - PubMed
  18. Oncol Lett. 2012 Apr 1;3(4):935-939 - PubMed
  19. Oncologist. 2008;13 Suppl 2:4-7 - PubMed
  20. J Clin Oncol. 2010 Feb 20;28(6):1061-8 - PubMed
  21. Br J Cancer. 2010 Mar 2;102(5):803-9 - PubMed
  22. Jpn J Clin Oncol. 2010 Dec;40(12 ):1166-72 - PubMed
  23. J Clin Oncol. 2007 May 1;25(13):1760-4 - PubMed
  24. N Engl J Med. 2013 Aug 22;369(8):722-31 - PubMed
  25. J Clin Oncol. 2007 May 1;25(13):1753-9 - PubMed
  26. Oncol Lett. 2013 Dec;6(6):1707-1712 - PubMed
  27. AJR Am J Roentgenol. 2004 Dec;183(6):1619-28 - PubMed
  28. Clin Cancer Res. 2008 Nov 15;14(22):7272-83 - PubMed
  29. BMC Cancer. 2009 Jul 21;9:249 - PubMed
  30. Onco Targets Ther. 2015 Jun 08;8:1363-73 - PubMed
  31. Jpn J Clin Oncol. 2012 Sep;42(9):836-44 - PubMed

Publication Types